Betamethasone 17-benzoate
| Code | Size | Price |
|---|
| TAR-T16152-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Betamethasone 17-benzoate is a representative steroid. It also can be used in the treatment of recurrent aphothous ulcers (RAU).
CAS:
22298-29-9
Formula:
C29H33FO6
Molecular Weight:
496.575
Pathway:
Cytoskeletal Signaling
Purity:
0.98
SMILES:
[H][C@@]12C[C@H](C)[C@](OC(=O)c3ccccc3)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Target:
Kinesin
References
1. Barry BW, et al. Optimization of bioavailability of topical steroids: penetration enhancers under occlusion. J Invest Dermatol. 1984 Jan;82(1):49-52.
2. ZFA (Stuttgart). 1978 Jul 10;54(19):1031-2.
3. Merchant HW, et al. Betamethasone-17-benzoate in the treatment of recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol. 1978 Jun;45(6):870-5.